Synthesis of "Statistical Innovations for Cost-Effectiveness Analysis"

Research Initiative in Clinical Economics

Research

Research Products

This research team has enjoyed many years of fruitful collaboration which has produced several publications in peer-reviewed journals, abstracts and invited presentations at professional meetings. Listed below are the research products.

Publications

  1. Gardiner J, Hogan A, Holmes-Rovner M, Rovner D, Griffith L, Kupersmith J. Confidence-Intervals for Cost-Effectiveness Ratios. Medical Decisionmaking 1995;15(3):254-63.
  2. Kupersmith J, Hogan A, Guerrero P, Gardiner J, et al. Evaluating and Improving the Cost-Effectiveness of the Implantable Cardioverter-Defibrillator. American Heart Journal 1995;130(3):507-15.
  3. Kupersmith J, Holmes-Rovner M, Hogan A, Rovner D, Gardiner J. Cost-effectiveness analysis in heart-disease. 1. General principles. Progress in Cardiovascular Diseases 1994;37(3):161-184.
  4. Kupersmith J, Holmes-Rovner M, Hogan A, Rovner D, Gardiner J. Cost-effectiveness analysis in heart-disease. 2. Preventive therapies. Progress in Cardiovascular Diseases 1995;37(4):243-71.
  5. Kupersmith J, Holmes-Rovner M, Hogan A, Rovner D, Gardiner J. Cost-effectiveness analysis in heart-disease. 3. Ischemia, congestive-heart-failure, and arrhythmias. Progress in Cardiovascular Diseases 1995;37(5):307-46.
  6. Gardiner J, Holmes-Rovner M, Goddeeris J, Rovner D, Kupersmith J. Covariate-adjusted cost-effectiveness ratios. Journal of Statistical Planning and Inference 1999;75(2):291-304.
  7. Gardiner JC, Huebner M, Jetton J, Bradley CJ. Power and sample size assessments for tests of hypotheses on cost-effectiveness ratios. Health Economics 2000;9(3):227-34.
  8. Gardiner JC, Bradley CJ, Huebner M. The cost-effectiveness ratio in the analysis of health care programs. In: Rao CR, Sen PK, eds. Handbook of Statistics, Bioenvironmental and Public Health Statistics. New York: North-Holland, 2000: 841-69.
  9. Gardiner JC, Huebner M, Jetton J, Bradley CJ. On parametric confidence intervals for the cost-effectiveness ratio. Biometrical Journal 2001;43(3):283-96.
  10. Indurkhya A, Gardiner JC, Luo Z. The effect of outliers on confidence interval procedures for cost-effectiveness ratios. Statistics in Medicine 2001;20(9-10):1469-77.
  11. Gardiner JC, Indurkhya A, Luo Z. The performance of estimation procedures for cost-effectiveness ratios. In: Balakrishnan N, ed., Advances on Methodological and Applied Aspects of Probability and Statistics. New York: Taylor & Francis, 2002: 547-59.
  12. Gardiner JC, Polverejan E. Longitudinal models for the analysis of health care costs and outcomes. Proceedings of the American Statistical Association, Section on Health Policy Statistics [CD-ROM] 2002, New York, NY.
  13. Gardiner JC, Luo Z, Bradley CJ, Polverejan E, Holmes-Rovner M, Rovner D. Longitudinal assessment of cost in health care interventions. Health Services & Outcomes Research Methodology 2002;3:148-69.
  14. Polverejan E, Gardiner JC, Bradley CJ, Holmes-Rovner M, Rovner D. Estimating mean hospital cost as a function of length of stay and patient characteristics. Health Economics 2003;12:935-47.
  15. Bradley CJ, Given CW, Baser O, Gardiner JC. Influence of surgical and treatment choices on the cost of breast cancer care. European Journal of Health Economics 2003;4:96-101.
  16. Baser O, Bradley CJ, Gardiner JC, Given CW. Testing and correcting for non-random selection bias due to censoring: An application to medical costs. Health Services & Outcomes Research Methodology 2003;4:93-107.
  17. Rahbar MH, Sikorski A, Gardiner JC. Regression analysis of medical costs with right censored data in the presence of discrete covariates. Proceedings of the American Statistical Association: Biometrics Section [CD-ROM] 2003, Alexandria, VA: American Statistical Association.
  18. Baser O, Gardiner JC, Bradley CJ, Yuce H, Given CW. Longitudinal analysis of censored medical costs data. In Review. 2003.
  19. Baser O, Bradley CJ, Gardiner JC, Given CW. Testing and correcting for non-random selection bias due to censoring: An application to medical costs. Health Services & Outcomes Research Methodology 2003; 4:93-107.
  20. Baser O, Bradley CJ, Gardiner JC. Estimation from censored medical costs. Biometrical Journal 2004 46:351-63.
  21. Gardiner JC, Sirbu CM, Rahbar MH. Update on sample size and power assessments for cost-effectiveness studies. Expert Review of Pharmacoeconomics & Outcomes Research 2004 4(1):89-98.
  22. Rahbar MH, Gardiner JC. Nonparametric modeling of the mean survival time in a multi-factor design based on randomly right-censored data. Biometrical Journal 2004;46(5):497-502.
  23. Gardiner JC, Sirbu CM. Estimating medical costs from a transition model. In Review. 2004.
  24. Corser WD, Gardiner JC, DeFranco A, Holmes-Rovner M, Sirbu CM, Watson RE, Kupersmith J. Changes in acute myocardial infarction procedure rates and subsequent patient mortality. In Review. 2004.
  25. Evonich RF, Maheshwari A, Gardiner JC, Khasnis A, Kantipudi S, Ip JH, et al. Implantable cardioverter defibrillator therapy in patients with ischemic or non-ischemic cardiomyopathy and nonsustained ventricular tachycardia. Journal of Interventional Cardiac Electrophysiology 2004;11(1):59-65.
  26. Bradley CJ, Gardiner JC, Given CW, Roberts CR. Cancer, Medicaid enrollment and survival disparities. Cancer 2005.

Abstracts and Presentations

  1. Guererro P, Hogan A, Gardiner J, Mellits D, Baumgardner R, Levine J, Rovner D, Holmes-Rovner M, Griffith L, Kupersmith J.� Strategies to improve cost effectiveness of the implantable cardioverter defibrillator. Clinical Research 1993; 41(2):122a, presented.
  2. Guererro P, Hogan A, Gardiner J, Mellits D, Baumgardner R, Levine J, Rovner D, Holmes-Rovner M, Griffith L, Kupersmith J. New approach to determination of cost/effectiveness of the implantable cardioverter defibrillator. Clinical Research 1993; 41(2):234a, presented.
  3. Guererro P, Hogan A, Gardiner J, Mellits D, Baumgardner R, Rovner D, Holmes-Rovner M, McLane A, Levine J, Griffith L, Kupersmith J.� Relationship of cost effectiveness of the transthoracic implantable cardioverter defibrillator to patient category and clinical strategy. Circulation Supplement 1993; 88:I-44.
  4. Guererro P, Hogan A, Gardiner J, Mellits D, Baumgardner R, Rovner D, Holmes-Rovner M, McLane A, Levine J, Saksena S, Griffith L, Kupersmith J. Improving the cost effectiveness of the Transvenous Implantable Cardioverter Defibrillator. Journal of the American College of Cardiology 1994; 23:206a.
  5. Gardiner J, Hogan A, Holmes-Rovner M, Rovner D, Griffith L, Kupersmith J.� Estimation of confidence intervals for average cost-effectiveness and cost-effectiveness ratios from survival data. �Clinical Research 1994; 42(2):224a, presented.
  6. Hogan A, Saksena S, Gardiner J, Mellits ED, Baumgardner RA, Rovner DR, Holmes-Rovner M, McLane AM, Levine J, Griffith L, Kupersmith J. The subpectoral transvenous implantable cardioverter defibrillator is a cost effective intervention.� American College of Cardiology 44th Annual Scientific Session, 1994.
  7. Gardiner J, Hogan A, Holmes-Rovner M, Rovner D, Griffith L, Kupersmith J. Confidence intervals for cost-effectiveness ratios. Biometrics Society 1995, presented.
  8. Gardiner J, Holmes-Rovner M, Rovner D, Goddeeris J, Kupersmith J.� Cost-effectiveness ratios in multi-state Markov models. Biometrics Society, Spring Meeting, 1996, Richmond, VA, presented.
  9. Abela G, Mitra R, Dwamena F, Gardiner J, Vasilenko P, Kroll J, Kupersmith J. Elevation in blood glucose is associated with complications during myocardial infarction—MICH Study.� American Heart Association 69th Session, 1996.
  10. Dwamena F, Mitra R, Watson R, Gardiner J, Abela G, Vasilenko P, Kupersmith J. Do community physicians prescribe angiotensin-converting enzyme inhibitors to patients with acute myocardial infarction?—MICH Study. American Heart Association 69th Session 1996.
  11. Watson R, Mitra R, Dwamena F, Kroll J, Vasilenko P, McIntosh B, Gardiner J, Manfred Stommel, Kupersmith J. Race influences the rate of cardiac catheterization, but does not influence the rate of PTCA and CABG following acute myocardial infarction?—MICH Study. American Heart Association 69th Session 1996.
  12. Gardiner J, Holmes-Rovner M, Rovner D, Goddeeris J, Kupersmith J.� Covariate-adjusted cost-effectiveness ratios. Biometrics Society, Spring Meeting, 1997, Memphis, TN, presented.
  13. Gardiner J, Holmes-Rovner M, Rovner D, Goddeeris J, Kupersmith J.� Covariate-adjusted cost-effectiveness ratios. Society for Medical Decisionmaking, Annual Meeting, 1997, Houston, TX, presented.
  14. Gardiner J, Huebner M, Jetton J, Bradley CJ. Power assessments and confidence intervals for cost-effectiveness analyses. Medical Decisionmaking 1998;18(4):465, presented.
  15. Gardiner J, Huebner M, Jetton J, Bradley, C.� Power assessments and confidence intervals for cost-effectiveness studies. International Indian Statistical Association, 1998, McMaster University, Canada, presented.
  16. Bradley CJ, Gardiner JC, Luo Z, Holmes-Rovner M, Rovner D.� The Health and Activities Limitation Index: A means to estimate for population-based quality-adjusted life years. Society for Medical Decisionmaking. Submitted. 1999.
  17. Gardiner JC, Polverejan E, Pathak PK. Modeling costs and health outcomes jointly: Application to cost-effectiveness analyses. Society for Medical Decisionmaking: Med Decis Making 1999; 19 (4):542, presented
  18. Polverejan E, Gardiner JC, Holmes-Rovner M, Rovner D. Joint analysis of in-hospital length of stay and cost. Biometrics Society, Spring Meeting, 2000, Chicago, IL, presented.
  19. Polverejan E, Gardiner JC, Holmes-Rovner M, Rovner D. A multivariate model to assess jointly the correlates of length of stay and hospital cost associated with cardiac procedures.� Society for Medical Decisionmaking. Submitted, 2000.
  20. Polverejan E, Gardiner JC. Estimating medical cost in longitudinal studies. Biometrics Society, Spring Meeting, 2001, Charlotte NC, presented.
  21. Luo Z, Rappley MD, Gardiner JC. Analyzing health care utilization with count regression models: application to children in Michigan Medicaid. Biometrics Society, Spring Meeting, 2001, Charlotte NC, presented
  22. Gardiner JC, Luo Z,� Polverejan E, Bradley CJ, Holmes-Rovner M, Rovner D. Longitudinal assessment of cost in health care interventions. Biometrics Society, Spring Meeting, 2002, Arlington, VA, presented.
  23. Gardiner JC, Polverejan E. Longitudinal assessment of cost in health care interventions: Application to cost-effectiveness analysis. Joint Statistical Meetings, American Statistical Association, 2002, New York, NY, presented.
  24. Bradley CJ, Given CW, Baser,O, Gardiner JC. Initial surgery determines subsequent costs of breast cancer care. Med Decisionmaking 2002:22(6);540, presented.
  25. Soundarraj D, Evonich R, Gardiner J, Mungee� S, Khasnis A, Kantipudi S, Ip J, Thakur RK. Inappropriate therapy in patients with ischemic cardiomyopathy compared to patients with non-ischemic cardiomyopathy. XIIth and World Congress on Cardiac Pacing Electrophysiology, 2003, Hong Kong, presented.
  26. Soundarraj D, Evonich R, Gardiner J, Mungee� S, Khasnis A, Kantipudi S, Ip J, Hayter G, Thakur RK. Do dual chamber ICDs reduce the incidence of inappropriate ICD therapy (IT)? XIIth and World Congress on Cardiac Pacing Electrophysiology, 2003, Hong Kong, submitted.
  27. Baser O, Bradley CJ, Gardiner JC, Given CW. Testing and correcting for nonrandom sample selection bias due to censoring. Society for Medical Decisionmaking, 2003, Chicago IL, presented.
  28. Gardiner JC, Sirbu CM. Assessing medical costs from a transition model. Symposium on Health Policy Analysis and Health Services Research, 2003, Portland, ME, presented.
  29. Gardiner JC. New developments in cost-effectiveness analysis. Joint Statistical Meetings, American Statistical Association 2003, San Francisco, CA, presented.
  30. Gardiner JC. Estimating costs and outcomes from a longitudinal model. International Conference on Healthcare Policy Research, 2003, Chicago, IL, presented.
  31. Sirbu CM, Gardiner JC. A transition model for assessing medical costs. Biometrics Society, Spring Meeting, 2004, Pittsburgh, PA, presented.
  32. Gardiner JC, Luo Z, Sirbu CM, Bradley CJ, Given CW. A multi-state stochastic model for assessing covariate effects on survival and cost. Society for Medical Decisionmaking 2004, Atlanta, GA.

Selected References

1. Levit K, Smith C, Cowan C, Lazenby H, Sensenig A, Catlin A. Trends in U.S. health care spending, 2001. Health Affairs 2003;22(1):154-64.

2. Garber AM. Advances in CE Analyses. In: Culyer AJ, Newhouse JP, editors. Handbook of Health Economics. Amsterdam: Elsevier Science BV, 2000:181-221.

3. Commonwealth of Australia. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including major submissions involving economic analyses. Canberra: Australian Government Publishing Service. 2002.

4. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada. 2nd ed. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA). 1997.

5. National Institute for Clinical Excellence: Technology appraisals work programme, new guidance documents, 2001.

6. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd Edition. Baltimore: Williams & Wilkins, 1996.

7. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.

8. Brouwer WBF, Koopmanschap MA. On the economic foundations of CEA. Ladies and gentlemen, take your positions! Journal of Health Economics 2000;19(4):439-59.

9. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. Journal of Health Economics 1997;16(1):1-31.

10. WHO. Constitution of the World Health Organization, Basic Documents. Geneva: World Health Organization, 1948.

11. Gardiner JC, Bradley CJ, Huebner M. The cost-effectiveness ratio in the analysis of health care programs. In: Rao CR, Sen PK, editors. Handbook of Statistics, Bioenvironmental and Public Health Statistics. New York: North-Holland, 2000:841-69.

12. Blumenschein K, Johannesson M, Yokoyama KK, Freeman PR. Hypothetical versus real willingness to pay in the health care sector: results from a field experiment. Journal of Health Economics 2001;20(3):441-57.

13. Kupersmith J, Holmes-Rovner M, Hogan A, Rovner D, Gardiner J. Cost-effectiveness analysis in heart-disease. 1. General principles. Progress in Cardiovascular Diseases 1994;37(3):161-84.

14. Fairclough DL. Design and Analysis of Quality of Life Studies in Clinical Trials. Boca Raton: Chapman & Hall/CRC, 2002.

15. Royston P. Analysis of quality of life data in controlled clinical trials. Statistical Methods in Medical Research 2002;11(1):1-2.

16. Glick HA, Briggs AH, Polsky D. Quantifying stochastic uncertainty and presenting results of cost-effectiveness analyses. Expert Review of Pharmacoeconomics & Outcomes Research 2001;1(1):25-36.

17. Gardiner JC, Huebner M, Jetton J, Bradley CJ. On parametric confidence intervals for the cost-effectiveness ratio. Biometrical Journal 2001;43(3):283-96.

18. Stinnett AA, Mullahy J. Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis. Medical Decisionmaking 1998;18(2):S68-S80.

19. Lothgren M, Zethraeus N. Definition, interpretation and calculation of cost- effectiveness acceptability curves. Health Economics 2000;9(7):623-30.

20. Gardiner JC, Polverejan E. Longitudinal models for the analysis of health care costs and outcomes. Proceedings of the American Statistical Association, Section on Health Policy Statistics [CD-ROM], 2002.

21. Gardiner JC, Sirbu CM. Estimation of medical costs from a transition model. Submitted, in review. 2004.

22. Corser WD, Gardiner JC, Sirbu CM, Holmes-Rovner M, DeFranco A, Watson RE. Changes in acute myocardial infarction procedure rates and subsequent patient mortality. Submitted, in review. 2003.

23. Polverejan E, Gardiner JC, Bradley CJ, Holmes-Rovner M, Rovner D. Estimating mean hospital cost as a function of length of stay and patient characteristics. Health Economics 2003;12(11):935-47.

24. Gardiner JC, Luo Z, Bradley CJ, Polverejan E, Holmes-Rovner M, Rovner D. Longitudinal assessment of cost in health care interventions. Health Services & Outcomes� Research Methodology 2002;3:149-68.

25. Gardiner J, Hogan A, Holmes-Rovner M, Rovner D, Griffith L, Kupersmith J. Confidence-intervals for cost-effectiveness ratios. Medical Decisionmaking 1995;15(3):254-63.

26. Gardiner J, Holmes-Rovner M, Goddeeris J, Rovner D, Kupersmith J. Covariate-adjusted cost-effectiveness ratios. Journal of Statistical Planning and Inference 1999;75(2):291-304.

27. Kupersmith J, Hogan A, Guerrero P, Gardiner J, Mellits ED, Baumgardner R, et al. Evaluating and improving the cost-effectiveness of the implantable cardioverter-defibrillator. American Heart Journal 1995;130(3):507-15.

28. Beck JR, Pauker SG. The Markov Process in Medical Prognosis. Medical Decisionmaking 1983;3(4):419-58.

29. Briggs A, Sculpher M. Markov models of medical prognosis—Commentary. British Medical Journal 1997;314(7077):354-5.

30. Briggs A, Sculpher M. An introduction to Markov modeling for economic evaluation. Pharmacoeconomics 1998;13(4):397-409.

31. Sonnenberg FA, Beck JR. Markov-Models in Medical Decisionmaking—a Practical Guide. Medical Decisionmaking 1993;13(4):322-38.

32. O'Brien BJ, Drummond MF, Labelle RJ, Willan A. In search of power and significance—issues in the design and analysis of stochastic cost-effectiveness studies in health-care. Medical Care 1994;32(2):150-63.

33. Willan AR, Obrien BJ. Confidence intervals for cost-effectiveness ratios: An application of Fieller's theorem. Health Economics 1996;5(4):297-305.

34. Chaudhary MA, Stearns SC. Estimating confidence intervals for cost-effectiveness ratios: An example from a randomized trial. Statistics in Medicine 1996;15(13):1447-58.

35. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: A non-parametric approach to confidence interval estimation. Health Economics 1997;6(4):327-40.

36. Laska EM, Meisner M, Siegel C. Statistical inference for cost-effectiveness ratio. Health Economics 1997;6(3):229-42.

37. Gardiner JC, Huebner M, Jetton J, Bradley CJ. Power and sample size assessments for tests of hypotheses on cost-effectiveness ratios. Health Economics 2000;9(3):227-34.

38. Gardiner JC, Sirbu CM, Rahbar MH. Update on statistical power and sample size assessments for cost-effectiveness studies. Expert Review of Pharmacoeconomics & Outcomes Research 2004;4(1):89-98.

39. Briggs AH, Gray AM. Power and sample size calculations for stochastic cost-effectiveness analysis. Medical Decisionmaking 1998;18(2):S81-S92.

40. Laska EM, Meisner M, Siegel C. Power and sample size in cost-effectiveness analysis. Medical Decisionmaking 1999;19(3):339-43.

41. Al MJ, Van Hout BA, Michel BC, Rutten FFH. Sample size calculation in economic evaluations. Health Economics 1998;7(4):327-35.

42. Backhouse ME. Use of randomised controlled trials for producing cost-effectiveness evidence—Potential impact of design choices on sample size and study duration. Pharmacoeconomics 2002;20(15):1061-77.

43. Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost- effectiveness plane. Health Economics 1998;7(8):723-40.

44. Wakker P, Klaassen MP. Confidence-Intervals for Cost/Effectiveness Ratios. Health Economics 1995;4(5):373-81.

45. Polsky D, Glick HA, Willke R, Schulman K. Confidence intervals for cost-effectiveness ratios: A comparison of four methods. Health Economics 1997;6(3):243-52.

46. Willan A, O'Brien BJ. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem (vol 5, pg 297, 1996). Health Economics 1999;8(6):559.

47. Heitjan DF, Moskowitz AJ, Whang W. Bayesian estimation of cost-effectiveness ratios from clinical trials. Health Economics 1999;8(3):191-201.

48. O'Hagan A, Stevens JW, Montmartin J. Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio. Pharmacoeconomics 2000;17(4):339-49.

49. Gardiner JC, Indurkhya A, Luo Z. The performance of estimation procedures for cost-effectiveness ratios. In: Balakrishnan N, editor. Advances on Methodological and Applied Aspects of Probability and Statistics. New York: Taylor & Francis, 2002:547-59.

50. Indurkhya A, Gardiner JC, Luo ZH. The effect of outliers on confidence interval procedures for cost-effectiveness ratios. Statistics in Medicine 2001;20(9-10):1469-77.

51. Jiang G, Wu J, Williams GR. Fieller's interval and the bootstrap-Fieller interval for the incremental cost-effectiveness ratio. Health Services & Outcomes� Research Methodology 2000;1(3-4):291-303.

52. Briggs AH, Mooney CZ, Wonderling DE. Constructing confidence intervals for cost-effectiveness ratios: An evaluation of parametric and non-parametric techniques using Monte Carlo simulation. Statistics in Medicine 1999;18(23):3245-62.

53. Weintraub WS, Cole J, Tooley JF. Cost and cost-effectiveness studies in heart failure research. American Heart Journal 2002;143(4):565-76.

54. Weintraub WS, Mahoney EM, Ghazzal ZMB, King SB, Culler SD, Morris DC, et al. Trends in outcome and costs of coronary intervention in the 1990s. American Journal of Cardiology 2001;88(5):497-503.

55. Kupersmith J, Holmesrovner M, Hogan A, Rovner D, Gardiner J. Cost-Effectiveness Analysis in Heart-Disease. 3. Ischemia, Congestive-Heart-Failure, and Arrhythmias. Progress in Cardiovascular Diseases 1995;37(5):307-46.

56. Kupersmith J, Holmesrovner M, Hogan A, Rovner D, Gardiner J. Cost-Effectiveness Analysis in Heart-Disease .2. Preventive Therapies. Progress in Cardiovascular Diseases 1995;37(4):243-71.

57. O'Brien BJ, Connolly SJ, Goeree R, Blackhouse G, Willan A, Yee R, et al. Cost-effectiveness of the implantable cardioverter-defibrillator—Results from the Canadian Implantable Defibrillator Study (CIDS). Circulation 2001;103(10):1416-21.

58. Larsen G, Hallstrom A, McAnulty J, Pinski S, Olarte A, Sullivan S, et al. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias—Results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy. Circulation 2002;105(17):2049-57.

59. Epstein AE, Conti JB, Curtis AB, Hess PG, Iansmith DH, Lott JW, et al. Antiarrhythmics Versus Implantable Defibrillators (Avid) —Rationale, Design, and Methods. American Journal of Cardiology 1995;75(7):470-75.

60. Mushlin AI, Hall WJ, Zwanziger J, Gajary E, Andrews M, Marron R, et al. The cost-effectiveness of automatic implantable cardiac defibrillators: Results from MADIT. Circulation 1998;97(21):2129-35.

61. Coats AJS. MADIT II, the Multi-center Autonomic Defibrillator Implantation Trial II stopped early for mortality reduction, has ICD therapy earned its evidence-based credentials? International Journal of Cardiology 2002;82(1):1-5.

62. O'Brien B, Connolly S, Goeree R, Blackhouse G, Willan A, Yee R, et al. Cost-effectiveness of the implantable cardioverter defibrillator: Results from the Canadian Implantable Defibrillator Study (CIDS). Journal of the American College of Cardiology 2000;35(2):152A-153A.

63. Evonich RF, Maheshwari A, Gardiner JC, Khasnis A, Kantipudi S, Ip JH, et al. Implantable cardioverter defibrillator therapy in patients with ischemic or non-ischemic cardiomyopathy and nonsustained ventricular tachycardia. Journal of Interventional Cardiac Electrophysiology 2004;11(1):59-65.

64. Hlatky MA, Bigger T. Cost-effectiveness of the implantable cardioverter defibrillator? Lancet 2001;357(9271):1817-8.

65. Weiss JP, Saynina O, McDonald KM, McClellan MB, Hlatky MA. Effectiveness and cost-effectiveness of implantable cardioverter defibrillators in the treatment of ventricular arrhythmias among Medicare beneficiaries. American Journal of Medicine 2002;112(7):519-27.

66. Gardiner J, Hogan A, Kupersmith J, Holmesrovner M, Rovner D, Griffith L. Estimation of confidence-intervals for average cost-effectiveness and cost-effectiveness ratios from survival-data. Clinical Research 1994;42(2):A224.

67. Parmigiani G. Modeling in Medical Decision Making-A Bayesian Approach. New York: Wiley & Sons, Inc, 2002.

68. Spath MA, O'Brien BJ. Cost effectiveness of implantable cardioverter defibrillator therapy versus drug therapy for patients at high risk of sudden cardiac death. Pharmacoeconomics 2002;20(11):727-38.

69. Sanders GD, Hlatky MA, Every NR, McDonald KM, Heidenreich PA, Parsons LS, et al. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Annals of Internal Medicine 2001;135(10):870-83.

70. Thompson S. Statistical issues in cost-effectiveness analyses. Statistical Methods in Medical Research 2002;11(6):453-4.

71. Watson RE, Stein AD, Dwamena RC, Kroll J, Mitra R, McIntosh BA, et al. Do race and gender influence the use of invasive procedures? Journal of General Internal Medicine 2001;16(4):227-34.

72. AHCPR Guidelines Panel. Depression in Primary Care: Detection and Diagnosis. Rockville, MD: U.S. Department of Health and Human Services, Agency for Healthcare Policy & Research, Pub #93-0550, 1993.

73. Sacristan JA, Day SJ, Navarro O, Ramos J, Hernandez JM. Use of confidence-intervals and sample-size calculations in health economic-studies. Annals of Pharmacotherapy 1995;29(7-8):719-25.


Internet Citation:

Synthesis of "Statistical Innovations for Cost-Effectiveness Analysis".� February 2005. Agency for Healthcare Research and Quality, Rockville, MD.�http://www.ahrq.gov/rice/gardsum.htm


 

Current as of February 2005
Internet Citation: Synthesis of "Statistical Innovations for Cost-Effectiveness Analysis": Research Initiative in Clinical Economics. February 2005. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/professionals/clinicians-providers/resources/rice/gardsum3.html